StockNews.com Begins Coverage on Eagle Pharmaceuticals (NASDAQ:EGRX)

StockNews.com assumed coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a research report released on Wednesday morning. The brokerage issued a hold rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Stock Up 16.1 %

Shares of EGRX stock opened at $0.65 on Wednesday. Eagle Pharmaceuticals has a fifty-two week low of $0.00 and a fifty-two week high of $6.81. The stock’s 50-day moving average is $0.69 and its two-hundred day moving average is $2.75.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of EGRX. Creative Planning bought a new stake in Eagle Pharmaceuticals in the third quarter worth $59,000. Mackenzie Financial Corp bought a new position in Eagle Pharmaceuticals during the second quarter valued at about $60,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Eagle Pharmaceuticals in the second quarter worth about $65,000. Fidelis Capital Partners LLC bought a new stake in shares of Eagle Pharmaceuticals during the 2nd quarter worth about $71,000. Finally, Vanguard Personalized Indexing Management LLC acquired a new position in shares of Eagle Pharmaceuticals during the 2nd quarter valued at about $76,000. Institutional investors and hedge funds own 85.36% of the company’s stock.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.